In this issue:
Risk of CVD with high-dose vs low-dose NSAIDs in AS
Diagnosing AS in chronic back pain in less than 2 years
Patients with PsA-related enthesitis and persistence on tofacitinib
Residual disease activity in patients with PsA treated with advanced therapies
The impact of psoriasis on wellbeing and clinical outcomes
Risk of infections in PsA or AS in patients treated with targeted therapies
Fear of movement in patients with axSpA
Erosions on T1 weighted MRI vs radiography in recent-onset axSpA
Comparison of NSAIDs vs anti-TNF therapy alone
Predicting PsA in psoriasis patients
Please login below to download this issue (PDF)